أمراض الكُلى وارتفاع ضغط الدم

بالأسفل التجارب السريرية الحالية.

غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.

1. Rare Kidney Stone Consortium Patient Registry

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to collect medical information from a large number of patients in many areas of the world with primary hyperoxaluria (PH), Dent disease, Cystinuria and APRT deficiency. This information will create a registry that will help us to compare similarities and differences in patients and their symptoms. The more patients we are able to enter into the registry, the more we will be able to understand the Primary Hyperoxalurias,Dent disease, cystinuria and APRT and learn better ways of caring for patients with these diseases.

2. OBINUTUZUMAB in Treatment of Fibrillary Glomerulonephritis

   Rochester, Minn.

   The purpose of this study is to determine if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis.

3. A Study of Genes that cause Cystic Kidney Disease

   Rochester, Minn.

   The overall objective of this study is to define genes causing cystic kidney disease and to determine the degree to which variants at these cystic kidney disease genes underlie the clinical diversity of these disorders. This will provide an insight into the disease mechanisms, and explore novel mutation screening methods.  A combination of mutation screening in clinically characterized human cystic kidney disease populations, gene hunting and exploration of incompletely penetrant alleles in humans will provide a comprehensive picture of how mutations cause the resulting phenotype.

4. Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits (PGNMID)

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with  monoclonal immunoglobulin deposits (PGNMID) by assessing improvement in proteinuria at 12 months.

   Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and cytopenias.

5. Biobank Protocol, Rare Diseases Clinical Research Network

   Rochester, Minn.

   This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.

6. A Study to Form a Database of Children with Kidney Stone Disease

   Rochester, Minn.

   The purpose of this study is to establish a database to collect and analyze information on metabolic and environmental risk factors for kidney stone formation in children.

7. A Study to Evaluate How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease

   Rochester, Minn.

   The purpose of this study is to evaluate whether or not semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will receive semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.

8. Obstructive Sleep Apnea Among Somali-Americans

   Rochester, Minn.

   The purpose of this study is to advance the understanding of obstructive sleep apnea as it relates to different ethnic origins as well as sex differences. The investigators will compare Somali patients with known obstructive sleep apnea (OSA) to individuals without OSA, and to individuals of other ethnic/racial origins to determine the risk factors (genetic and/or physiologic) associated with developing cardiovascular diseases. This will help the investigators to understand the unique sleep pathology of individuals of African descent.

9. REstrictive versus LIberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI)

   Rochester, Minn.

   The objective of this study is to evaluate the feasibility of alternative Net Ultrafiltration (UFNET) rate strategies among critically ill adults with acute kidney injury (AKI) and treated with Continuous Kidney Replacement Therapy (CKRT).

    

10. A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea

    Rochester, Minn.

    Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue.

بالأسفل التجارب السريرية الحالية.

غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.

1. Rare Kidney Stone Consortium Patient Registry

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to collect medical information from a large number of patients in many areas of the world with primary hyperoxaluria (PH), Dent disease, Cystinuria and APRT deficiency. This information will create a registry that will help us to compare similarities and differences in patients and their symptoms. The more patients we are able to enter into the registry, the more we will be able to understand the Primary Hyperoxalurias,Dent disease, cystinuria and APRT and learn better ways of caring for patients with these diseases.

2. OBINUTUZUMAB in Treatment of Fibrillary Glomerulonephritis

   Rochester, Minn.

   The purpose of this study is to determine if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis.

3. A Study of Genes that cause Cystic Kidney Disease

   Rochester, Minn.

   The overall objective of this study is to define genes causing cystic kidney disease and to determine the degree to which variants at these cystic kidney disease genes underlie the clinical diversity of these disorders. This will provide an insight into the disease mechanisms, and explore novel mutation screening methods.  A combination of mutation screening in clinically characterized human cystic kidney disease populations, gene hunting and exploration of incompletely penetrant alleles in humans will provide a comprehensive picture of how mutations cause the resulting phenotype.

4. Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits (PGNMID)

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with  monoclonal immunoglobulin deposits (PGNMID) by assessing improvement in proteinuria at 12 months.

   Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and cytopenias.

5. Biobank Protocol, Rare Diseases Clinical Research Network

   Rochester, Minn.

   This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.

6. A Study to Form a Database of Children with Kidney Stone Disease

   Rochester, Minn.

   The purpose of this study is to establish a database to collect and analyze information on metabolic and environmental risk factors for kidney stone formation in children.

7. A Study to Evaluate How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease

   Rochester, Minn.

   The purpose of this study is to evaluate whether or not semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will receive semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.

8. Obstructive Sleep Apnea Among Somali-Americans

   Rochester, Minn.

   The purpose of this study is to advance the understanding of obstructive sleep apnea as it relates to different ethnic origins as well as sex differences. The investigators will compare Somali patients with known obstructive sleep apnea (OSA) to individuals without OSA, and to individuals of other ethnic/racial origins to determine the risk factors (genetic and/or physiologic) associated with developing cardiovascular diseases. This will help the investigators to understand the unique sleep pathology of individuals of African descent.

9. A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea

   Rochester, Minn.

   Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue.

10. REstrictive versus LIberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI)

    Rochester, Minn.

    The objective of this study is to evaluate the feasibility of alternative Net Ultrafiltration (UFNET) rate strategies among critically ill adults with acute kidney injury (AKI) and treated with Continuous Kidney Replacement Therapy (CKRT).